<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911413</url>
  </required_header>
  <id_info>
    <org_study_id>TXA dosage trial 2</org_study_id>
    <nct_id>NCT04911413</nct_id>
  </id_info>
  <brief_title>Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery</brief_title>
  <official_title>Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of three different dose levels of tranexamic acid（TXA）in&#xD;
      reducing blood loss and transfusion requirements in cardiac valve surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of TXA to reduce perioperative blood loss and blood transfusion has been well&#xD;
      established in many trials, but the optimal dosage of TXA in cardiac surgery has always been&#xD;
      a problem of debate. This is a single-center randomized controlled trial to study different&#xD;
      dose regimens of TXA in cardiac surgery. We use three different dose levels of TXA in cardiac&#xD;
      valve surgery with CPB, and see if there are any differences in perioperative blood loss and&#xD;
      transfusion requirements. Serious adverse events and seizure attacks are also recorded until&#xD;
      three months after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">March 5, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total postoperative drainage</measure>
    <time_frame>from the operation day to the discharge，an average of 7 days</time_frame>
    <description>The total chest tube drainage postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red blood cells transfusion rate（%），Red blood cells transfusion volume（ml）</measure>
    <time_frame>from the operation day to the discharge，an average of 7 days</time_frame>
    <description>intraoperative and postoperative RBC transfusion rate and transfusion volume（for all patients and for transfused patients）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fresh frozen plasma transfusion rate（%），Fresh frozen plasma transfusion volume（ml）</measure>
    <time_frame>from the operation day to the discharge，an average of 7 days</time_frame>
    <description>intraoperative and postoperative FFP transfusion rate and transfusion volume（for all patients and for transfused patients）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusion rate（%），Platelet transfusion volume（ml）</measure>
    <time_frame>from the operation day to the discharge，an average of 7 days</time_frame>
    <description>intraoperative and postoperative platelet transfusion rate and transfusion volume（for all patients and for transfused patients）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>repeat surgery because of bleeding</measure>
    <time_frame>from the operation day to the discharge，an average of 7 days</time_frame>
    <description>rate of repeat surgery due to massive bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of death</measure>
    <time_frame>from the operation day to three months after surgery</time_frame>
    <description>rate of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seizure attack</measure>
    <time_frame>from the operation day to three months after surgery</time_frame>
    <description>any seizure attack is recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in ICU and hospital</measure>
    <time_frame>from the operation day to the discharge，an average of 7 days</time_frame>
    <description>the length of stay in ICU and hospital</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Cardiac Surgical Procedures</condition>
  <condition>Blood Transfusion</condition>
  <condition>Tranexamic Acid</condition>
  <arm_group>
    <arm_group_label>low-dose group,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bolus of 10 mg/kg Tranexamic Acid followed by a maintenance dose of 10 mg/kg/h Tranexamic Acid until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle-dose group,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bolus of 20 mg/kg Tranexamic Acid followed by a maintenance dose of 15 mg/kg/h Tranexamic Acid until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bolus of 30 mg/kg Tranexamic Acid followed by a maintenance dose of 20 mg/kg/h Tranexamic Acid until the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.</description>
    <arm_group_label>high-dose group</arm_group_label>
    <arm_group_label>low-dose group,</arm_group_label>
    <arm_group_label>middle-dose group,</arm_group_label>
    <other_name>Cyklokapron</other_name>
    <other_name>Transamin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients aged between 18 to 60 years old scheduled for cardiac valve surgery&#xD;
             (replacement or plasty) requiring CPB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to TXA, combined CABG operation or other cardiac procedures other than&#xD;
             valve surgery, previous cardiac surgery, EF&lt;45% or cardiothoracic ratio&gt;0.65, serious&#xD;
             coagulation disorder, serious hepatic insufficiency, receiving antiplatelet therapy at&#xD;
             any time within 7 days of surgery, receiving low molecular weight heparin at any time&#xD;
             within 24 hours of surgery, and pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuwai Hospital, National Center for Cardiovascular Diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Director，the department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Dose regimen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

